Table 4.
Subgroup analysis according to menopausal status
| Variable | Metachronous overall CRN |
Metachronous ACRN |
||
|---|---|---|---|---|
| Crude HR (95% CI) | Adjusted HR (95% CI)a | Crude HR (95% CI) | Adjusted HR (95% CI)a | |
| Total women (n = 1,263) | ||||
| NAFLD (−) (n = 987) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| NAFLD (+) (n = 276) | 1.97 (1.55–2.52) | 1.65 (1.27–2.14) | 2.66 (1.28–5.53) | 2.25 (1.02–4.95) |
| Premenopausal women (n = 863) | ||||
| NAFLD (−) (n = 720) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| NAFLD (+) (n = 143) | 1.37 (0.92–2.05) | 1.37 (0.90–2.09) | 2.55 (0.88–7.39) | 2.90(0.93–9.07) |
| Postmenopausal women (n = 400) | ||||
| NAFLD (−) (n = 267) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| NAFLD (+) (n = 133) | 2.04 (1.47–2.83) | 1.88 (1.32–2.67) | 2.32 (0.81–6.67) | 1.67 (0.57–4.88) |
Of the 1,523 female patients, 1,263 (82.9%) had available data on menopausal status.
CRN, colorectal neoplasia; ACRN, advanced colorectal neoplasia; HR, hazard ratio; CI, confidence interval; NAFLD, nonalcoholic fatty liver disease.
a
Values were adjusted for NAFLD, age, current or former smoking, family history of colorectal cancer, use of nonsteroidal anti-inflammatory drugs, regular exercise, and baseline adenoma characteristics.